Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 42 of 42 publications.

Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S119. doi: 10.1016/j.jval.2023.09.772

Yee KS, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT. Orphanet J Rare Dis. 2023 Nov 2;18(1):343. doi: 10.1186/s13023-023-02957-2

Mladsi D, Barnett CL, Mader G, Russell-Smith TA, Tuson H, Unuigbe A, Bell T. The zero-price conundrum: exploration of scenarios where a clinically effective new drug might not be cost-effective at zero price. Value Health. 2023 Mar;26(3):384-91. doi: 10.1016/j.jval.2023.01.004.

Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8

Barnett CL, Denton BT. Optimization of biomarker-based prostate cancer screening policies. In: Sze-chuan Suen, David Scheinker, Eva Enns, editors. Artificial intelligence for healthcare: interdisciplinary partnerships for analytics-driven improvements in a post-COVID world. Cambridge: United Kingdom. Cambridge University Press; 2022. p.141-58.

Ronquest NA, Paret K, Gould I, Barnett CL, Mladsi (she/her) DM. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports. J Manag Care Spec Pharm. 2021 Nov;27(11):1601-12. doi: 10.18553/jmcp.2021.27.11.1601

Yee KS, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. Assessment of cognitive development in patients with neuronopathic Mucopolysaccharidosis II treated with intrathecal idursulfase-IT using Projected Retained Ability Score (PRAS): a post hoc analysis. Poster presented at the 2021 World Conference on Quality and Improvement; May 24, 2021.

Gandola AE, Ait Sarkouh R, Orfanos P, Bouisset F, Licitra L, Bourhis J, Mladsi D, Chirila C, Paret K, Barnett C. An early cost-effectiveness analysis of xevinapant in combination with chemo-radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck in United States. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.

Ronquest N, Paret K, Gould I, Barnett CL, Mladsi D. Effects of stakeholder engagement with Icer on cost-effectiveness of new interventions: lessons learned from a critical review of evaluations from 2018 to 2019. Presented at the Virtual ISPOR 2021 Conference; May 2021.

Merdan S, Barnett CL, Denton BT, Montie JE, Miller DC. OR practice–data analytics for optimal detection of metastatic prostate cancer. Oper Res. 2021 May;69(3):2-4. doi: 10.1287/opre.2020.2020

Yee K, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. Using projected retained ability score to assess cognitive development in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT. Poster presented at the 2021 ACMG Annual Clinical Genetics Virtual Meeting; April 2021.

Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772

Aggarwal K, Vredenburg M, Mladsi D, Barnett C. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 2020 AMCP Meeting (Conference cancelled); April 2020. [abstract] J Manag Care Pharm. 2020 Apr; 26(Supplement 4a):s58.

Mladsi D, Hess LM, Barnett CL, Njue A, Huang YJ, Cui ZL, Bowman L. Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study. J Med Econ. 2020 Mar;23(3):213-20. doi: 10.1080/13696998.2019.1678479

Barnett C, Davenport MS, Montgomery JS, Kunju LP, Denton B, Piert M. 18F-choline PET/mpMRI for detection of significant prostate cancer, part 2: cost-effectiveness analysis. J Nucl Med. 2019 Dec;60(12):1705-12. doi: 10.2967/jnumed.119.225771

Allen LF, Aggarwal K, Vredenburg M, Barnett C, Mladsi D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Poster presented at the 61st ASH American Society of Hematology Annual Meeting and Exposition; December 8, 2019. San Diego, CA. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):3454. doi: 10.1182/blood-2019-131822

Lucas A, Sinha A, Fowler KB, Mladsi D, Barnett C, Samant S, Gibson L. A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States. Cost Eff Resour Alloc. 2019 Oct 3;17(1):21. doi: 10.1186/s12962-019-0189-0

Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shanka PR, Rajendiran T, Shao X, Lee E, Barnett CL, Denton BT, Piert M. 18F-choline PET/mpMRI for detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies. J Nucl Med. 2019 Aug 16. doi: 10.2967/jnumed.119.225789.

Ronquest NA, Gould IG, Barnett CL, Mladsi DM. A systematic review of ICER evaluations from 2008 to 2018: recent trends in evaluation process and lessons learned. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(2):S263-4.

Mladsi DM, Barnett CL, Kaye JA. Identification of potential bias from data sources and study designs used to estimate platelet transfusion adverse event rates. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Lucas A, Sinha A, Fowler KB, Mladsi D, Barnett C, Samant S, Gibson L. A framework for assessing the lifetime economic burden of congenital cytomegalovirus in the United States. Poster presented at the 2018 Congenital Cytomegalovirus (CMV) Public Health & Policy Conference; September 24, 2018. Burlington, VT.

Barnett CL, Mladsi D, Vredenburg M, Aggarwal K. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018 Aug;21(8):827-34. doi: 10.1080/13696998.2018.1490301

Barnett CL, Davenport MS, Montgomery JS, Wei JT, Montie JE, Denton BT. Cost‐effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018 Jul;122(1):50-8.

Barnett CL, Auffenberg GB, Cheng Z, Yang F, Wang J, Wei JT, Miller DC, Montie JE, Mamawala M, Denton BT. Optimizing active surveillance strategies to balance the competing goals of early detection of grade progression and minimizing harm from biopsies. Cancer. 2018 Feb 15;124(4):698-705. doi: 10.1002/cncr.31101

Barnett CL, Tomlins SA, Underwood DJ, Wei JT, Morgan TM, Montie JE, Denton BT. Two-stage biomarker protocols for early detection of prostate cancer. Med Decis Making. 2017 Oct;37(7):815-26. doi: 10.1177/0272989X17696996

Barnett C, Auffenberg G, Cheng Z, Yang F, Wang J, Wei J, Miller D, Montie J. Can frequency of prostate biopsy on active surveillance be reduced without significantly increasing risk? Poster presented at the 112th American Urological Association Annual Meeting; May 2017. Boston, MA. [abstract] J Urol. 2017 Apr; 197(4 Supplement):e552-3. doi: 10.1016/j.juro.2017.02.1311

Barnett C, Denton BT. Developing near-optimal biomarker-based prostate cancer screening strategies. Presented at the 2016 INFORMS Annual Meeting; November 14, 2016. Nashville, TN.

Barnett C, Merdan S. Data analytics for optimal detection of metastatic prostate cancer. Presented at the 2016 INFORMS Annual Meeting; November 13, 2016. Nashville, TN.

Barnett C, Auffenberg GB, Cheng Z, Yang F, Wang J, Miller D. Optimization of active surveillance for minimally invasive early detection of cancer progression. Poster presented at the 2016 INFORMS Annual Meeting; November 2016. Nashville, TN.

Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611

Barnett C, Denton BT, Montie JE. Developing optimal biomarker-based prostate cancer screening policies. Presented at the 2015 INFORMS Annual Meeting; November 2, 2015. Philadelphia, PA.

Barnett C, Denton B, Montie T, Morgan T, Tomlins S, Underwood D, Wei J. Developing optimal biomarker-based screening strategies using reinforcement learning. Presented at the INFORMS Healthcare Conference 2015; July 29, 2015. Nashville, TN.

Risko R, Merdan S, Womble PR, Barnett C, Ye Z, Linsell SM, Montie JE, Miller DC, Denton BT. Clinical predictors and recommendations for staging computed tomography scan among men with prostate cancer. Urology. 2014 Dec;84(6):1329-34. doi: 10.1016/j.urology.2014.07.051

Barnett C, Denton B, Montie J, Morgan T, Tomlins S, Wei J. Developing optimal biomarker-based screening policies using reinforcement learning. Presented at the INFORMS Annual Meeting 2014; November 12, 2014. San Francisco, CA.

Merdan S, Womble PR, Miller DC, Barnett C, Ye Z, Linsell SM, Montie JE, Denton BT. Toward better use of bone scans among men with early-stage prostate cancer. Urology. 2014 Oct;84(4):793-8. doi: 10.1016/j.urology.2014.06.010

Barnett C, Tomlins S, Morgan TM, Denton BT. What are the public health implications of new biomarkers for prostate cancer screening? Poster presented at the 36th Annual Meeting of the Society for Medical Decision Making; October 2014. Miami, FL.

Barnett C, Tomlins SA, Underwood DJ, Wei JT, Morgan TM, Merdan S, Montie J, Denton B. Modeling the public health impacts of prostate cancer biomarkers in a screening setting. Presented at the Health Systems Optimization Workshop; April 2014. Chicago, IL.

Barnett C, Denton BT, Montie JE, Tomlins SA, Wei JT. Optimization of screening policies for newly discovered cancer biomarkers. Presented at the 2013 INFORMS Annual Meeting; October 2013. Minneapolis, MN.

Barnett C, Denton BT, Montie JE, Tomlins SA, Wei JT. Evaluation of new biomarkers for prostate cancer screening. Presented at the 2013 INFORMS Healthcare Conference; June 2013. Chicago, IL.

Barnett C, Muckstadt JA. Using simulation to assess public health emergency distribution networks: the emergency supply chain operations evaluator (ESCOE). Presented at the INFORMS Annual Meeting 2010; November 2010. Austin, TX.